- Home
- REPX vs OPT Comparison
REPX vs OPT Comparison
Compare REPX & OPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REPX
- OPT
- Stock Information
- Founded
- REPX 2016
- OPT 1984
- Country
- REPX United States
- OPT Australia
- Employees
- REPX N/A
- OPT N/A
- Industry
- REPX Oil & Gas Production
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- REPX Energy
- OPT Health Care
- Exchange
- REPX Nasdaq
- OPT Nasdaq
- Market Cap
- REPX 708.5M
- OPT 767.9M
- IPO Year
- REPX N/A
- OPT 2020
- Fundamental
- Price
- REPX $31.30
- OPT $3.27
- Analyst Decision
- REPX Strong Buy
- OPT Strong Buy
- Analyst Count
- REPX 1
- OPT 1
- Target Price
- REPX $45.00
- OPT $12.00
- AVG Volume (30 Days)
- REPX 100.1K
- OPT 13.2K
- Earning Date
- REPX 11-06-2024
- OPT 08-30-2024
- Dividend Yield
- REPX 4.75%
- OPT N/A
- EPS Growth
- REPX 12.34
- OPT N/A
- EPS
- REPX 5.64
- OPT N/A
- Revenue
- REPX $407,315,000.00
- OPT $261,859.00
- Revenue This Year
- REPX $13.27
- OPT N/A
- Revenue Next Year
- REPX $9.48
- OPT $46,864.64
- P/E Ratio
- REPX $5.67
- OPT N/A
- Revenue Growth
- REPX 15.30
- OPT N/A
- 52 Week Low
- REPX $21.27
- OPT $1.79
- 52 Week High
- REPX $37.15
- OPT $5.45
- Technical
- Relative Strength Index (RSI)
- REPX 43.64
- OPT 40.67
- Support Level
- REPX $31.40
- OPT $3.15
- Resistance Level
- REPX $33.01
- OPT $3.78
- Average True Range (ATR)
- REPX 1.09
- OPT 0.18
- MACD
- REPX -0.39
- OPT -0.00
- Stochastic Oscillator
- REPX 26.14
- OPT 25.91
About REPX Riley Exploration Permian Inc.
Riley Exploration Permian Inc is engaged in the business of exploration for and production of oil and natural gas. The company operations are in Kansas Properties, and Tennessee Properties, among others.
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.